Coronary Artery Disease
Conditions
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of spinous process balloon dilation catheter (Plastic-Blade) in coronary vascular diseases, which is not inferior to the similar product on the market - coronary spinous process balloon dilation catheter (lacrosse NSE) produced by Goodman Co., Ltd..
Detailed description
This study is a prospective, multicenter, randomized, controlled and non inferiority designed clinical trial. A total of 160 subjects with CAD from 8 centers will be randomized 1:1 to each group. All subjects evaluated the immediate lumen acquisition immediately after operation and the MACE of 30 ± 7 days after operation. The primary endpoint is the acquisition of lumen immediately after operation. The effectiveness of balloon was evaluated. The safety of balloon was evaluated by adverse events during operation.Clinical follow-up will be conducted at operation, discharge and 30 ± 7 days after operation. The target lesions included the following : opening lesions, bifurcation lesions, calcification lesions and fibrosis lesions; Diameter stenosis ≥ 70% (visual) with evidence of ischemia; Localized lesions with TIMI ≥ 1; RVD=2.00 and 4.00mm , and the vascular segment is suitable for balloon dilatation in anatomical structure。
Interventions
PROCEDUREspinous balloon dilatation catheter (Plastic-Blade)
To treat Coronary artery disease
PROCEDUREspinous balloon dilatation catheter(lacrosse NSE)
To treat Coronary artery disease
Sponsors
Shanghai 10th People's Hospital
CCRF Inc., Beijing, China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Masking description
During the study, it is difficult for researchers, operators and patients to blind the method due to objective reasons.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 1\. 18-75 years * 2.Stable or unstable angina, or previous myocardial infarction, or Asymptomatic ischemia judged by clinician ,Target vascular diameter: 2.00-4.00mm ,Coronary artery stenosis stenosis ≥ 70% by visual inspection, or ≥ 50% with evidence of ischemia, TIMI blood flow≥ 1,the operator judge that the patient needs spinous balloon to treat. * 3\. Paticipant can understand the study ,voluntarily participate in and sign the informed consent form,and accept scheduled follow-up.
Exclusion criteria
Patient related: * 1.Pregnant and breast-feeding women or intention to be pregnant. * 2.Subjects with MI within one week, or more than one week after the onset of MI,but TNI or TNT have not returned to normal. * 3.The spinous balloon failed to pass through the stenosis after small balloon dilation , and the lesion need to be rotary grinded. * 4\. Non-target vessel did not be dealed with successful before dealing with target vessel, or non-target vascular lesion number is more than three. * 5.Serious heart failure（NYHA IV） * 6.Severe renal failure（Cr\>443uMol/L) or patients undergoing hemodialysis. * 7.Patient with heart transplant. * 8.Patient with CABG. * 9.Patients with hemodynamic instability or shock symptoms. * 10.Life expectancy less than one year. * 11.Expected to undergo surgery within one month. * 12.Patients with bleeding tendency, history of active gastrointestinal ulcer, contraindications of antiplatelet or anticoagulant treatment, cannot receive anticoagulant treatment, and patients have hemorrhagic stroke within six months. * 13.Allergy to heparin and contrast agent. * 14.The illness of the patient make the treatment and evaluation difficult. * 15.Those who have participated in other drug or medical device trials have not reached main research endpoint. * 16.Clinicians estimated that the risk of intervention is very high or the patient should be excluded for other reasons. * 17.Poor of compliance Lesion related: * 18.Lesions of LAD or with a distance of ≤ 2mm beyond LAD. * 19.Angiogram showed thrombus. * 20.CTO,and TIMI blood flow=0, * 21.Coronary artery spasm * 22.Lesions of LAD without bypass surgery or collateral circulation protection. * 23.The doctor considered the patient unfit for the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immediate lumen acquisition | during the procedure | The difference of the minimum diameter of the target lesion before and after balloon dilatation in the test or control group measured by QCA. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of clinical success | from procedure to discharge ( to the 7th day after procedure) | Based on device success, no patient occurred composite endpoint (PoCE) during hospitalization |
| Incidence of related complications | 30 days after balloon dilatation | Including acute occlusion, vasospasm, vascular rupture, branch or collateral occlusion, subacute stent thrombosis, intimal tear, dissection, etc. |
| % change of clinically meaningful laboratory tests | 30 days after procedure | Record the change of clinically meaningful laboratory tests |
| Rate of device success | during the procedure | Proportion of patients who meet the success criteria. Success criteria be defined as the residual stenosis of the target lesion is less than 50% after balloon dilatation and the balloon delivery system is successfully withdrawn |
| Number of device related composite endpoint | 30 days | Including TLF, Cardiac Death, TV-MI and ID-TLR |
| Number of patient oriented composite endpoint | 30 days | Including all cause death, MI, TLR, TVR, Revascularization of any coronary arteries and thrombus at the lesion. |
| Total time of device operation performance | 30 days | Push capacity, passing capacity and withdrawal capacity |
| Number of adverse events | 30 days | Adverse events occurred during balloon dilatation, after balloon dilatation to 30 ± 7 days after discharge |
Contacts
Primary ContactYi Zhang, M.D.
Outcome results
None listed